Sansure Biotech released its 2026 interim report. First-half net profit attributable to the parent was 98.02 million yuan, down 39.8% year on year, while operating revenue was 834 million yuan, down 3.9% year on year. Second-quarter operating revenue was 397 million yuan, up 1.0% year on year, but net profit attributable to the parent was 48.28 million yuan, down 32.0% year on year. The company said that centralized procurement, medical insurance cost controls and payment reform led to lower reagent prices. The growth hormone products of its subsidiary Zhongshan Haiji were also affected by expanded medical insurance coverage and price cuts. At the same time, the value-added tax rate on self-produced testing reagents in the in vitro diagnostics industry was raised from 3% to 13%, which had a significant impact on profit. The company is increasing investment in instruments, research and development innovation, and industrial mergers and acquisitions, and sticking to its integrated diagnosis and treatment strategy to cope with short-term profit dilution.
Sansure Biotech IncFirst-half net profit fell 39.8% year on year due to lower reagent prices and higher VAT rate.
